The assessment of the efficacy of citicoline in the early and recovery stages of stroke

Close metadata

Recommended articles:

Multi-center open comparative randomized study of efficacy and safety of Akatinol Memantine 20 mg (single-doses) vs Akatinol Memantine 10 mg (double-doses) in patients with vascular dementia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(2):69-77

Cerebral amyloid angiopathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(2):85-90

The relationship between the development of post-stroke cognitive impairment and changes in the coagulation component of hemostasis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3-2):23-29

The effect of insomnia on mild cognitive impairment in patients with vascular risks: results of a three-year longitudinal study. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3-2):30-36

Cerebrolysin as an early add-on to reperfusion therapy: heterogeneous treatment effect analysis in ischemic stroke patients with varying risk of hemorrhagic transformation. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3-2):55-66

Efficacy of Mexidol in combination with cerebral revascularization in the treatment of ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3-2):67-74

Identifying the neurostimulation target for treatment of cognitive impairment in aging and early cerebral small vessel disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3):34-41

Asthenic disorders correction with Recognan. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3):57-62

Associations between components of metabolic syndrome and cognitive impairment in patients with schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3):82-87

Prevalence of cognitive impairment in older adults in the Russian Federation. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):5-11

The review presents data on the evaluation of the efficacy of citicoline in ischemic stroke. It presents research findings about the effect of citicoline to reduce infarct volume in animal models of cerebral ischemia. Long-term treatment of CDP-choline initiated 24 hours after stroke contributes to the increased plasticity of neurons in intact brain areas (functionally associated with the damaged areas) and accelerated functional recovery. The oral administration of citicoline within the first 24 hours after the onset of symptoms in moderate and severe stroke increases the probability of complete recovery in 3 months. A neuroprotective effect of citicoline in acute and early restorative stages of stroke accompanied by cognitive impairment was shown. According to the results of clinical trials of the dosage regimen, citicoline administered in the dose of 1000 mg/day for 8 weeks accelerates the regression of hemiplegia; the intravenous injection in the dose of 750 mg/day for 10 days, starting with the first 48 hours of stroke onset symptoms, promotes the recovery of motor and cognitive functions; the intravenous injection in the dose of 1 g within 14 days improves the recovery of consciousness, general condition and functional status.

Keywords:

citicoline

neuroprotection

stroke

cognitive impairment

List of references:

Levin OS. Primenenie citikolina v lechenii insul'ta. RMZh. 2008;16(26):1772-1778. (In Russ.).
Parfenov VA. Citikolin v lechenii cerebrovaskuljarnyh zabolevanij. Lechashhij vrach. 2007;8:72-74. (In Russ.).
Secades JJ. Citicoline: pharmacological and clinical review, 2010 update. Rev Neurol. 2011;52(suppl 2):1-62.
Plataras C, Taskiris S, Angelogianni P. Effect of CDP-choline on brain acetylcholinesterase and Na+/K+-ATPase in adult rats. Clin Biochem. 2000;33:351-357. doi: 10.1016/s0009-9120(00)00084-9.
Davalos A, Secades J. Citicoline preclinical and clinical update 2009—2010. Stroke. 2011;42(suppl 1):36-39. doi: 10.1161/strokeaha.110.605568.
Saver JL. Citicoline: update on a promising and widely available agent for neuroprotection and neurorepair. Rev Neurol Dis. 2008;5:167-177.
Molina CA. Reperfusion therapies for acute ischemic stroke current pharmacological and mechanical approaches. Stroke. 2011;42(suppl 1):16-19. doi:10.1161/strokeaha.110.598763.
Hurtado O, Moro MA, Cárdenas A, Sánchez V, Fernández-Tomé P, Leza JC, Lorenzo P, Secades JJ, Lozano R, Dávalos A, Castillo J, Lizasoain I. Neuroprotection afforded by prior citicoline administration in experimental brain ischemia: effects on glutamate transport. Neurobiol Dis. 2005;18(2):336-345. doi:10.1016/j.nbd.2004.10.006.
Hurtado O, Cardenas A, Pradillo J, Morales JR, Ortego F, Sobrino T, Castillo J, Moro MA, Lizasoain I. A chronic treatment with CDP-choline improves functional recovery and increases neuronal plasticity after experimental stroke. Neurobiol Dis. 2007;(26):105-111. doi:10.1016/j.nbd.2006.12.005.
Hurtado O, Lizasoain I, Moro MA. Neuroprotection and recovery recent data at the bench on citicoline. Stroke. 2011;42(suppl 1):33-35. doi:10.1161/strokeaha.110.597435.
Giralt D, García-Bonilla L, Campos M, Sosti V, Rosell A, Montaner J. Selecting the optimal dose of citicoline treatment in animal models of focal cerebral ischemia through a meta-analysis. Cerebrovasc Dis. 2010;29(suppl 2):165.
Aronowski J, Strong R, Grotta JC. Citicoline for treatment of experimental focal ischemia: histologic and behavioral outcome. Neurol Res. 1996;18(6):570-574. doi:10.1016/0028-3908(96)84640-5.
Clark WM, Warach SJ, Pettigrew LC, Gammans RE, Sabounjian LA. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Neurology. 1997;49:671-678. doi:10.1212/wnl.49.3.671.
Clark WM, Williams BJ, Selzer KA, Zweifler RM, Sabounjian LAA, Gammans RE. A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke. 1999;30:2592-2597. doi:10.1161/01.str.30.12.2592.
Tazaki Y, Sakai F, Otomo E, Kutsuzawa T, Kameyama M, Omae T, Fujishima M, Sakuma A. Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study. Stroke. 1988;19:211-216. doi:10.1161/01.str.19.2.211.
. Gammans RE, Sherman DG. ECCO 2000 study of citicoline for treatment of acute ischemic stroke: final results. 25th International Stroke Conference, New Orleans (USA). 2000.
Warach SJ, Sabounjian LA. ECCO 2000 study of citicoline for treatment of acute ischemic stroke: Effects on infarct volumes measured by MRI. 25th International Stroke Conference, New Orleans (USA). 2000.
Baskaya MK, Dogan A, Rao AM, Dempsey RJ. Neuroprotective effects of citicoline on brain edema and blood-brain barrier breakdown after traumatic brain injury. J Neurosurg. 2000;92(3):448-452. doi:10.3171/jns.2000.92.3.0448.
Adibhatla RM, Hatcher JF, Dempsey RJ. Citicoline: neuroprotective mechanisms in cerebral ischemia. J Neurochem. 2002;80:12-23. doi:10.1046/j.0022-3042.2001.00697.x.
Adibhatla RM, Hatcher JF. Cytidine 5'-diphosphocholine (CDPcholine) in stroke and other CNS disorders. Neurochem Res. 2005;30:15-23. doi: 10.1007/s11064-004-9681-8/
Davalos A, Castillo J, Alvarez-Sabin J, Secades JJ, Mercadal J, López S, Cobo E, Warach S, Sherman D, Clark WM, Lozano R. Oral citicoline in acute ischemic stroke. An individual patient data pooling analysis of clinical trials. Stroke. 2002;33:2850-2857. doi: 10.1161/01.str.0000038691.03334.71/
Davalos A, Alvarez-Sabín J, Castillo J, Díez-Tejedor E, Ferro J, Martínez-Vila E, Serena J, Segura T, Cruz VT, Masjuan J, Cobo E, Secades JJ. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet. 2012;380(9839):349-257. doi: 10.1016/s0140-6736(12)60813-7.
Alvarez-Sabin J, Roman GC. Citicoline in vascular cognitive impairment and vascular dementia after stroke. Stroke. 2011;42(suppl 1):40-43. doi: 10.1161/strokeaha.110.606509/
Chamorro A, Roman GC. Proceedings of recent developments and future directions in stroke management and prevention symposium. Stroke. 2011;42(suppl 1):1-2. doi:10.1161/strokeaha.110.608802.
Parnetti L, Mignini F, Tomassoni D. Cholinergic precursorsin the treatment of cognitive impairment of vascular origin. J Neurol Sci. 2007;257:264-269. doi: 10.1016/j.jns.2007.01.043.
Lee H, Kang J, Kim Y. Citicoline protects against cognitive impairment in a rat model of chronic cerebral hypoperfusion. J Clin Neurol. 2009;(5):33-38. doi: 10.3988/jcn.2009.5.1.33.
Gareri P, Castagna A, Cotroneo AM, Putignano S, De Sarro G, Bruni AC. The role of citicoline in cognitive impairment: pharmacological characteristics, possible advantages, and doubts for an old drug with new perspectives. Clin Interv Aging. 2015;10:1421-1429. doi: 10.2147/cia.s87886.
Shahparonova NV, Kadykov AS, Kashina EM. Postinsul'tnye kognitivnye narushenija i ih terapija ceraksonom. Nevrologija, nejropsihiatrija, psihosomatika. 2011;3:56-60. (In Russ.).
Shetova IM, Shamalov NA, Bocina AJu. Ispol'zovanie citikolina v ostrom periode cerebral'nogo insul'ta. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2009;12(2):51-54. (In Russ.).
Shavlovskaja OA. Nejroprotektivnaja terapija nevrologicheskogo deficita pri cerebrovaskuljarnoj patologii. Praktikujushhij vrach segodnja. 2012;3:39-44. (In Russ.).
Sergeev DV. Nejroprotekcija pri ishemicheskom insul'te: opravdany li nadezhdy? RMZh. 2010;18(26):1521-1526. (In Russ.).
Sergeev DV, Piradov MA. Nejroprotekcija — strategicheskoe napravlenie v lechenii ishemicheskogo insul'ta. RMZh. 2010;18(8):441-445. (In Russ.).
Skoromec TA. Sovremennaja terapija kognitivnogo deficita pri ostryh mozgovyh porazhenijah. Vestnik Rossijskoj voenno-medicinskoj akademii. 2015;4(52):117-121. (In Russ.).

Close metadata